» Articles » PMID: 20532236

Evaluating the Quality of Research into a Single Prognostic Biomarker: a Systematic Review and Meta-analysis of 83 Studies of C-reactive Protein in Stable Coronary Artery Disease

Abstract

Background: Systematic evaluations of the quality of research on a single prognostic biomarker are rare. We sought to evaluate the quality of prognostic research evidence for the association of C-reactive protein (CRP) with fatal and nonfatal events among patients with stable coronary disease.

Methods And Findings: We searched MEDLINE (1966 to 2009) and EMBASE (1980 to 2009) and selected prospective studies of patients with stable coronary disease, reporting a relative risk for the association of CRP with death and nonfatal cardiovascular events. We included 83 studies, reporting 61,684 patients and 6,485 outcome events. No study reported a prespecified statistical analysis protocol; only two studies reported the time elapsed (in months or years) between initial presentation of symptomatic coronary disease and inclusion in the study. Studies reported a median of seven items (of 17) from the REMARK reporting guidelines, with no evidence of change over time. The pooled relative risk for the top versus bottom third of CRP distribution was 1.97 (95% confidence interval [CI] 1.78-2.17), with substantial heterogeneity (I(2) = 79.5). Only 13 studies adjusted for conventional risk factors (age, sex, smoking, obesity, diabetes, and low-density lipoprotein [LDL] cholesterol) and these had a relative risk of 1.65 (95% CI 1.39-1.96), I(2) = 33.7. Studies reported ten different ways of comparing CRP values, with weaker relative risks for those based on continuous measures. Adjusting for publication bias (for which there was strong evidence, Egger's p<0.001) using a validated method reduced the relative risk to 1.19 (95% CI 1.13-1.25). Only two studies reported a measure of discrimination (c-statistic). In 20 studies the detection rate for subsequent events could be calculated and was 31% for a 10% false positive rate, and the calculated pooled c-statistic was 0.61 (0.57-0.66).

Conclusion: Multiple types of reporting bias, and publication bias, make the magnitude of any independent association between CRP and prognosis among patients with stable coronary disease sufficiently uncertain that no clinical practice recommendations can be made. Publication of prespecified statistical analytic protocols and prospective registration of studies, among other measures, might help improve the quality of prognostic biomarker research.

Citing Articles

2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part I.

Chao T, Lin T, Cheng C, Wu Y, Ueng K, Wu Y Acta Cardiol Sin. 2024; 40(5):479-543.

PMID: 39308649 PMC: 11413940. DOI: 10.6515/ACS.202409_40(5).20240724A.


Blood-based biomarkers and novel technologies for the diagnosis of colorectal cancer and adenomas: a narrative review.

Magowan D, Abdulshafea M, Thompson D, Rajamoorthy S, Owen R, Harris D Biomark Med. 2024; 18(9):493-506.

PMID: 38900496 PMC: 11285240. DOI: 10.1080/17520363.2024.2345583.


Genetic Evidence for the Causal Association of Circulating Cytokines and Growth Factors With Coronary Artery Disease.

Li Y, Liu B, Chen Y, Liu Z, Ye D, Mao Y J Am Heart Assoc. 2024; 13(2):e030726.

PMID: 38214249 PMC: 10926782. DOI: 10.1161/JAHA.123.030726.


Multi-proteomic Biomarker Risk Scores for Predicting Risk and Guiding Therapy in Patients with Coronary Artery Disease.

Gold M, Woods E, Pobee D, Ibrahim R, Quyyumi A Curr Cardiol Rep. 2023; 25(12):1811-1821.

PMID: 38079057 DOI: 10.1007/s11886-023-01995-3.


Aggregate Clinical and Biomarker-Based Model Predicts Adverse Outcomes in Patients With Coronary Artery Disease.

Desai S, Dhindsa D, Ko Y, Sandesara P, Mehta A, Liu C Am J Cardiol. 2023; 203:315-324.

PMID: 37517126 PMC: 10900119. DOI: 10.1016/j.amjcard.2023.06.115.


References
1.
Elliott P, Chambers J, Zhang W, Clarke R, Hopewell J, Peden J . Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009; 302(1):37-48. PMC: 2803020. DOI: 10.1001/jama.2009.954. View

2.
Romero-Corral A, Montori V, Somers V, Korinek J, Thomas R, Allison T . Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006; 368(9536):666-78. DOI: 10.1016/S0140-6736(06)69251-9. View

3.
Hlatky M, Greenland P, Arnett D, Ballantyne C, Criqui M, Elkind M . Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009; 119(17):2408-16. PMC: 2956982. DOI: 10.1161/CIRCULATIONAHA.109.192278. View

4.
Moreno S, Sutton A, Ades A, Stanley T, Abrams K, Peters J . Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study. BMC Med Res Methodol. 2009; 9:2. PMC: 2649158. DOI: 10.1186/1471-2288-9-2. View

5.
Hayden J, Cote P, Steenstra I, Bombardier C . Identifying phases of investigation helps planning, appraising, and applying the results of explanatory prognosis studies. J Clin Epidemiol. 2008; 61(6):552-60. DOI: 10.1016/j.jclinepi.2007.08.005. View